Jodie Pope Morrison, Keryx Biopharmaceuticals's Interim CEO and a director of the company, recently acquired 100,000 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on May 10, 2018. Morrison now owns 110,000 shares of the company. Morrison operates out of Boston, MA. Some additional info was provided as follows:
The 100,000 shares are restricted common stock, which will vest in full on October 31, 2018, conditioned upon Ms. Morrison's continued employment as Interim CEO and subject to other terms and conditions.
Includes 110,000 shares of restricted stock.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Keryx Biopharmaceuticals makes a similar move, sign up!